Injectable Drug Delivery Articles

51. Exploring Biolistic Particle Delivery Systems 2/29/2024

    The main objective of biolistic particle delivery is to insert genetic material or other molecules into cells or tissues for diverse applications, including genetic engineering, gene therapy, and plant modification. The ability to target substances into specific cells enables researchers to investigate gene functionality, alter genetic traits, or explore novel therapeutic strategies.

52. Use-Related Risk Analysis For Combination Products 2/7/2024

    One of the most integral components in the development of drug-device combination products is the use-related risk analysis (URRA) and its applicability to the overall human factors engineering process. Deficiencies in the URRA are a leading cause of delays with FDA submissions.

53. Foundational Human Factors Engineering Concepts For The Design Of Combination Products 2/5/2024

    How can companies keep pace with the demand in the combination products market while meeting or exceeding regulatory expectations of applying human factors engineering? This article provides an overview.

54. Auto-injectors: Global Trends & Market Forecast 1/30/2024

    Auto-injectors offer a dependable method for delivering medication, especially during emergency scenarios. This article shares new market research, including macro trends, smart features, disposable vs. reusable trends, and more.

55. Liposome Drug Delivery: Global Trends & Market Forecast 1/19/2024

    Liposomes possess the ability to encapsulate drugs of both hydrophilic and hydrophobic nature. They can be tailored to target tissues or cells, enabling precise drug delivery. Let's examine how it works, applications, and new market insights.

56. Is FDA's COVID Container Closure System Guidance Useful Post-Pandemic? 1/9/2024

    The COVID-era guidance is designed to help manufacturers make container closure system changes quickly when facing supply constraints. It may be useful when evaluating risks beyond the pandemic.

57. Drug Delivery Systems: Measurement System Analysis Using Continuous Gage R&R Studies, Part 3 12/20/2023

    This is the third article in a series of three articles. It continues the discussion of measurement system analysis using continuous gage R&D studies by sharing a generic example using Minitab. Study setup, the role of the study director, analysis, and case studies are examined.

58. Key Regulatory-Fueled Updates On Combination Products As We Enter 2024 12/15/2023

    In late November, AFDO/RAPS held their annual Combination Products Summit in Fort Worth, TX. The meeting is co-sponsored by the FDA with heavy involvement from the Office of Combination Products, and its representatives covered several themes on the subject as we prepare to enter 2024.

59. Best Practices For Preformulation In Drug Development 12/14/2023

    Preformulation testing encompasses all studies performed on a new drug compound in order to produce useful information for subsequent formulation of a suitable drug dosage form. There is preformulation across the stages of drug discovery, early development, and late development. The route of administration dictates what is important.

60. Midline Catheters Show Fastest Growth Rate In Vascular Access: A Global Market Analysis 12/12/2023

    In many situations, midline catheters present a superior choice compared to short peripheral catheters, which are suitable for brief indwelling periods, and PICCs, which carry a higher risk of central line-associated bloodstream infection (CLABSI) and are more complex to insert. Let's examine new market research.